Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.45 |
| ▸ | ITGAV | P06756 | 8/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978978 | 1.00 | FFAR1 (0.47) | FFAR1MTNR1AMTNR1BITGB3ITGAV | |
| SCHEMBL11677942 | 0.90 | MTNR1A (0.60) | FFAR1MTNR1AMTNR1BITGB3ITGAV | |
| SCHEMBL28528399 | 0.86 | HTR2A (0.60) | FFAR1MTNR1AMTNR1BITGB3ITGAV | |
| SCHEMBL10611457 | 0.83 | FFAR1 (0.41) | FFAR1MTNR1AMTNR1BITGB3ITGAV | |
| SCHEMBL8637266 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL1470461 | 0.81 | FFAR1 (0.62) | FFAR1MTNR1AMTNR1BPPARD | |
| SCHEMBL7845908 | 0.81 | FFAR1 (0.62) | FFAR1MTNR1AMTNR1BPPARD | |
| SCHEMBL7847075 | 0.81 | FFAR1 (0.62) | FFAR1MTNR1AMTNR1BPPARD | |
| SCHEMBL6634999 | 0.81 | MTNR1A (0.61) | FFAR1MTNR1AMTNR1BITGB3ITGAV | |
| SCHEMBL6643325 | 0.81 | ITGB3 (0.53) | FFAR1MTNR1AMTNR1BITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| EP-2970277-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Knopp Biosciences LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145852-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145852-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-5753662-A | TREATING DOPAMINERGIC SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 1998-05-19 | — | — | US | disclosed |
| US-5684020-A | ANTIPSYCHOTICS, ANTIDEPRESSANTS, TREATMENT OF DYSFUNCTION OF DOPAMINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1997-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KCNA7, KCNA2, KCNK17 | FFAR1 1354/4885MTNR1A 801/4885MTNR1B 956/4885 |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | FFAR1 1354/4885MTNR1A 801/4885MTNR1B 956/4885 |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | FFAR1 1269/4885MTNR1A 814/4885MTNR1B 1029/4885 |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | FFAR1 1354/4885MTNR1A 801/4885MTNR1B 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.